Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study
Authors:
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 104, 110050
Abstract
No abstract availableKeywords
Funding Information
- Fondazione Umberto Veronesi
- National Institute for Health Research
- GlaxoSmithKline
- Bristol-Myers Squibb
- Lundbeck
This publication has 102 references indexed in Scilit:
- GSK-3 Inhibition Potentiates the Synaptogenic and Antidepressant-Like Effects of Subthreshold Doses of KetamineNeuropsychopharmacology, 2013
- Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male miceJournal of Psychiatry and Neuroscience, 2013
- Use of insulin sensitizers for the treatment of major depressive disorder: A pilot study of pioglitazone for major depression accompanied by abdominal obesityJournal of Affective Disorders, 2012
- Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidityBehavioural Brain Research, 2011
- Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in miceMolecular Psychiatry, 2011
- AKT Kinase Activity Is Required for Lithium to Modulate Mood-Related Behaviors in MiceNeuropsychopharmacology, 2011
- GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSFrontiers in Molecular Neuroscience, 2011
- Is Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?Neuropsychopharmacology, 2010
- Zinc supplementation augments efficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled studyJournal of Affective Disorders, 2009
- Synthetic small molecules that control stem cell fateProceedings of the National Academy of Sciences, 2003